This Practice Alert highlights some recent practice issues reported to PDL Professional Officers. Respiratory Syncytial Virus (RSV) vaccines Currently, two Respiratory Syncytial Virus (RSV) vaccines,
During your healthcare career, you may receive a regulatory notification. Regulatory notifications are a mechanism for the public to raise any concerns about their healthcare experience
Pharmacists would be aware of the down scheduling of some nicotine vaping or e-cigarette products to S3 from 1 October 2024. PDL has recently provided
NSW pharmacists The oral contraceptive resupply component of the NSW Pharmacy Trial ceased on 27 September 2024. From 28 September 2024, NSW pharmacists holding general
PDL has recently released the Practice Alert ‘Be aware or beware of wrong patient errors – part 1’. This second alert follows up to provide
From 1 October 2024, therapeutic vapes with a nicotine concentration of 20mg/mL or less will be available in pharmacies to patients 18 years or over
Following the recent direction from the Chief Pharmacist Department of Health SA, PDL advises that SA pharmacists may lawfully administer the following medicines: An unscheduled,
The Pharmacy Stakeholder Forum is a joint initiative between the Pharmacy Council of NSW, NSW Ministry of Health and other pharmacy organisations representing most NSW
Pharmacists are likely aware that Wegovy® (semaglutide) is now available in Australia. The PDL Professional Officers have received several incident reports involving patients being supplied
The Wrong Patient incident type is a subset of dispensing incidents that continue to be highly reported to PDL. This almost entirely preventable error occurs
Pharmaceutical Defence Limited (PDL) acknowledges the Traditional Owners of Country throughout Australia and their continuing connection to land, waters and community. We pay our respects to the people, the cultures and the Elders past and present.